Ganciclovir 82410-32-0

Function of Ganciciovir

Ganciclovir (GCV) is suitable for blind cytomegalovirus retinitis caused by severe immune function, AIDS, organ transplantation, malignant tumors, etc., as well as pneumonia, gastroenteritis, liver and central nervous system CMV infections

Ganciclovir  is a derivative of acyclovir (ACV). GCV was developed in the United States in 1983, and clinical trials began in 1984. In 1988, the United States, France and the United Kingdom began to sell in 15 countries. Japan implemented clinical trials in 1988, and was manufactured and sold as a rare drug in 1990.

*Products under the patent are only for R&D use